Cyclerion Therapeutics
CYCN
73 hedge funds and large institutions have $66.9M invested in Cyclerion Therapeutics in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 13 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
0% more funds holding
Funds holding: 73 → 73 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
0.16% less ownership
Funds ownership: 3.38% → 3.22% (-0.16%)
52% less capital invested
Capital invested by funds: $140M → $66.9M (-$72.7M)
63% less call options, than puts
Call options by funds: $21K | Put options by funds: $57K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.2M |
| 2 |
Two Sigma Investments
New York
|
+$367K |
| 3 |
QI
QS Investors
New York
|
+$350K |
| 4 |
D.E. Shaw & Co
New York
|
+$285K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$276K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.36M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.87M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$420K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$272K |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$240K |
CYCN Hedge Fund Activity: Q4 2020 in Review
73 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q4 2020, worth a combined $66.9M — down 52% from $140M a quarter earlier.
Fund positioning in CYCN was balanced in Q4 2020: 13 funds opened new positions, 13 closed out, 23 added to existing stakes and 19 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.2M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $4.36M sold.
- 73 institutional investors held Cyclerion Therapeutics (CYCN) as of Q4 2020, unchanged from Q3 2020.
- Funds reported $66.9M of Cyclerion Therapeutics stock for Q4 2020, down 52% quarter-over-quarter.
- 13 funds opened new Cyclerion Therapeutics positions in Q4 2020 and 13 closed out, a net change of 0 holders.
- The largest Cyclerion Therapeutics buyer in Q4 2020 was Morgan Stanley, an estimated $1.2M added.
- The largest Cyclerion Therapeutics seller in Q4 2020 was T. Rowe Price Associates, an estimated $4.36M sold.
Based on aggregated 13F filings for Q4 2020.